Back to Search Start Over

Supplementary Methods, Figures 1 - 7 from HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

Authors :
Max S. Wicha
Hasan Korkaya
Daniel F. Hayes
Dafydd G. Thomas
Celina G. Kleer
Mark L. Day
Whitney A. Chadwick
Shawn G. Clouthier
Tahra K. Luther
Nader Tawakkol
Amber N. Heath
Nallasivam Palanisamy
Christopher L. Hall
April Davis
Stephanie Daignault
Kathleen Woods Ignatoski
Ahmed A. Quraishi
Tom F. Bersano-Begey
Scott J. Dawsey
Qin Zen
Fayaz Malik
Kathleen C. Day
Suthinee Ithimakin
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

PDF file - 491K, Supplementary Figure 3. Effect of trastazumab on stem cell marker expression. Supplementary Figure 2. Trastuzumab inhibits tertiary tumorsphere formation in luminal cell lines. Supplementary Figure 1. Representative FACS analysis demonstrating an overlap between HER2 expression and ALDH activity. Supplementary Figure 4. Trastuzumab treatment or HER2 gene knockdown reduces tumorsphere formation of MCF7 cells. Supplementary Figure 5. Rank mediated upreglation of HER2 expression in MCF7 cells. Supplementary Figure 6. Elevated HER2 expression in bone metastasis compared to matched primary luminal tumors is not due to HER2 gene amplification. Supplemental Figure 7. No significant differences in HER2 protein expression were found in matched primary tumors and bone metastasis in women with HER-positive breast cancer.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....560abdc1fd7d537096d1f2568089c598